Gendicine (recombinant human p53 adenovirus [Ad5RSV-p53]), was approved by the China Food and Drug Administration (CFDA) in 2003 for the treatment of HNSCC [137,138,139]. Here, TP53 is linked to head and neck squamous cell carcinoma.